The interplay of the gut microbiome, tryptophan metabolites, and uremic toxin generation in chronic kidney disease progression

Abstract

Chronic kidney disease (CKD) affects roughly 850 million people worldwide, yet the cardiovascular and immune-related mortality that classical uremic markers cannot fully explain remains the central clinical problem. Much of the small-solute uremic toxin pool is now traceable to gut microbial metabolism, and tryptophan-derived metabolites – generated by both bacterial and host pathways – sit at the center of this picture. Across the CKD spectrum, the intestinal microbiome shifts toward proteolytic, indole-generating, and urease-positive taxa while fiber-fermenting commensals decline. Two tryptophan pathways drive most of the downstream injury: The host kynurenine route, amplified by interferon-γ-driven indoleamine 2,3-dioxygenase activation, and the bacterial indole route, which generates indoxyl sulfate (IS), indole-3-acetic acid (IAA), and indole-3-propionic acid (IPA). These metabolites converge on the aryl hydrocarbon receptor but produce opposite outcomes: IS, IAA, and kynurenine drive an injurious Nuclear factor kappa B/NOD-, LRR- and pyrin domain-containing 3/transforming growth factor beta 1 program, while IPA, depleted in CKD, supports gut barrier integrity and dampens inflammation. In adjusted Cox models, IS independently predicts cardiovascular and all-cause mortality (hazard ratio [HR] 2.10/1-standard deviation log-IS, 95% confidence interval [CI] 1.37–3.23) and p-cresyl sulfate predicts renal progression (HR 1.092 per μmol/L, 95% CI 1.060–1.126). Plant-dominant, fiber-rich dietary patterns remain the best-supported intervention; synbiotics produce modest surrogate-level benefit, and oral spherical carbon adsorbent (AST-120) is regionally approved but failed its primary composite endpoint in the multinational EPPIC-1/2 trials. The next generation of trials must use validated biomarker thresholds, ligand-selective interventions, hard renal and cardiovascular endpoints, and cohorts beyond Europe and East Asia.